8-K: Zynex Reports 17% Revenue Growth for 2023, Announces $20 Million Share Repurchase Plan

Zynex, Inc. reported a 17% increase in revenue for 2023, reaching $184.3 million, and announced a new $20 million stock repurchase program.

Summary

• Zynex, Inc. announced its financial results for the fourth quarter and full year of 2023, showing a 17% increase in revenue for the full year, reaching $184.3 million.
• The company's fourth-quarter revenue decreased by 3% year-over-year to $47.3 million, primarily due to a $6.2 million non-recurring write-off of slow-collecting receivables.
• Full-year net income was $9.7 million, with diluted earnings per share (EPS) of $0.27, while fourth-quarter net income was $1.2 million, with diluted EPS of $0.04.
• Orders increased by 43% year-over-year for the full year and 29% year-over-year for the fourth quarter, marking the seventh consecutive quarter of record orders.
• Zynex achieved a record cash flow from operations of $17.8 million for the full year, a 29% increase year-over-year.
• The company repurchased $38.4 million of its common stock in 2023 and has authorized an additional $20 million stock repurchase plan.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, record orders, and a new stock repurchase plan. While there are some negative aspects, such as the Q4 revenue decrease and write-off, the overall tone is optimistic and forward-looking.

Positives

• Full-year revenue increased by 17% to $184.3 million.
• Orders increased by 43% year-over-year for the full year.
• Record cash flow from operations of $17.8 million for the full year, a 29% increase year-over-year.
• The company has a strong cash position with $44.6 million in cash and cash equivalents as of December 31, 2023.
• The company has a new $20 million share repurchase plan.
• The company received FDA clearance for the M-Wave NMES device.
• The company expects a 22% increase in net revenue for 2024.
• The company expects an 85% increase in diluted EPS for 2024.

Negatives

• Fourth-quarter revenue decreased by 3% year-over-year to $47.3 million.
• The fourth-quarter revenue was impacted by a $6.2 million non-recurring write-off of slow-collecting receivables.
• Fourth-quarter net income decreased to $1.2 million, or $0.04 per diluted share, compared to $7.5 million, or $0.20 per diluted share, in the same quarter of the previous year.
• Adjusted EBITDA for the full year decreased to $22.3 million from $28.1 million in the previous year.
• Adjusted EBITDA for the fourth quarter decreased to $9.9 million from $11.4 million in the same quarter of the previous year.

Risks

• The company's future performance is subject to risks including the acceptance of new products, competition, technological changes, and reimbursement from health insurance companies.
• The company is dependent on third-party manufacturers to produce products on time and to specifications.
• The company's stock repurchase plan may be suspended or discontinued at any time.
• The company's future performance is subject to economic factors, such as interest rate fluctuations.

Future Outlook

Zynex expects 2024 net revenue to increase approximately 22% compared to 2023, reaching at least $227 million, and diluted EPS is expected to be at least $0.50 per share, an 85% increase compared to 2023. The company plans to focus on new products and expand its bracing line of products.

Management Comments

• 2023 was a year of continued execution for Zynex, underscored by record revenues and order numbers, and exciting new products and technological innovation, said Thomas Sandgaard, President and CEO of Zynex.
• A strong cadence of increasing sales and profitable growth for our pain management division delivered a 43% improvement in orders year-over-year.
• Our continued profitability and record positive cash flow allowed us to announce an additional $20 million share repurchase plan in the fourth quarter which is almost complete as of today.
• We are in a unique position to deliver solid revenue growth and profitability that allows us to invest in the business and return cash to shareholders at the same time, concluded Sandgaard.

Industry Context

Zynex operates in the medical technology sector, specifically focusing on non-invasive pain management and rehabilitation devices. The company's growth and product development align with the increasing demand for non-pharmacological pain management solutions and the trend towards home-based healthcare.

Comparison to Industry Standards

• Zynex's 17% revenue growth for 2023 is strong compared to some of its competitors in the medical device industry, such as Nevro Corp which reported a 10% increase in revenue for 2023.
• The 43% increase in orders for the full year is a significant achievement, indicating strong market demand for Zynex's products.
• The company's gross profit margin of 79% is competitive within the medical device industry, although some companies like Intuitive Surgical have higher margins.
• The stock repurchase program is a positive sign for investors, indicating management's confidence in the company's future prospects, similar to other companies like Stryker that have also implemented share buyback programs.
• Zynex's focus on non-invasive pain management aligns with the industry trend towards less invasive treatment options, similar to companies like Halyard Health.

Stakeholder Impact

• Shareholders will benefit from the stock repurchase plan and the positive financial results.
• Employees may benefit from the company's growth and success.
• Customers will have access to new and innovative pain management solutions.
• Suppliers may benefit from increased orders and business with Zynex.

Next Steps

• The company will commence the $20 million stock repurchase plan on March 4, 2024.
• The company will continue to focus on new product development and expanding its product line.
• The company will aggressively promote its bracing line of products as well as traction, cold/post-op and compression products.

Key Dates

Keywords

Zynex, Medical Devices, Pain Management, Rehabilitation, Stock Repurchase, Financial Results, Revenue Growth, EBITDA, FDA Clearance, NMES